CẬP NHẬT ĐIỀU TRỊ XUẤT HUYẾT GIẢM TIỂU CẦU HUYẾT KHỐI
Nội dung chính của bài viết
Tóm tắt
Xuất huyết giảm tiểu cầu huyết khối là bệnh lý cấp cứu có nguy cơ tử vong cao nếu không được điều trị kịp thời. Tình trạng tái phát, kháng trị cũng là một vấn đề nan giải cần được bổ sung các phương pháp điều trị mới. Bên cạnh trao đổi huyết tương và Corticoid là biện pháp điều trị hàng 1, các thuốc kháng CD20, Caplacizumab (kháng thụ thể A1- vị trí gắn tiểu cầu), thuốc nhắm mục tiêu tế bào Plasmo là những phương pháp điều trị mới được áp dụng và đưa vào các hướng dẫn điều trị uy tín trên thế giới.
Từ khóa
Xuất huyết giảm tiểu cầu huyết khối, điều trị, TTP
Chi tiết bài viết
Tài liệu tham khảo
1. Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021;10(3):536.
2. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor | Blood | American Society of Hematology. Accessed August 25, 2023. https://ashpublications.org/blood/article/118/12/3212/28806/Unraveling-the-scissile-bond-how-ADAMTS13
3. Lotta LA, Valsecchi C, Pontiggia S, et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2014;12(3):329-336.
4. Kim HJ, Xu Y, Petri A, et al. Crystal structure of ADAMTS13 CUB domains reveals their role in global latency. Sci Adv. 2021;7(16):eabg4403.
5. Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237-e245.
6. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura | Hematology, ASH Education Program | American Society of Hematology. Accessed June 23, 2022. https://ashpublications.org/hematology/article/2015/1/631/20558/What-s-new-in-the-diagnosis-and-pathophysiology-of
7. Heath AB, Kremer Hovinga JA, Hubbard AR. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(6):1151-1153.
8. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
9. Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70(6):319-323.
10. Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion. 2008;48(2):349-357.
11. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study | Annals of Hematology. Accessed August 3, 2024. https://link.springer.com/article/10.1007/s00277-009-0877-5
12. Bergstrand M, Hansson E, Delaey B, et al. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura. J Clin Pharmacol. 2022;62(3):409-421.
13. Owattanapanich W, Wongprasert C, Rotchanapanya W, et al. Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2019;25:1076029618825309.
14. Zwicker JI, Muia J, Dolatshahi L, et al. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood. 2019;134(13):1106-1109.
15. Knoebl P, Cataland S, Peyvandi F, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479-485.
16. Scully M, Rayment R, Clark A, et al. A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol. 2023;203(4):546-563.
17. Djulbegovic M, Tong J, Xu A, et al. Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood Adv. 2023;7(10):2132-2142.
18. Lee NCJ, Yates S, Rambally S, et al. Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single-centre retrospective cohort and systematic literature review. Br J Haematol. 2024;204(2):638-643.
19. van den Berg J, Kremer Hovinga JA, Pfleger C, et al. Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(3):993-997.
2. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor | Blood | American Society of Hematology. Accessed August 25, 2023. https://ashpublications.org/blood/article/118/12/3212/28806/Unraveling-the-scissile-bond-how-ADAMTS13
3. Lotta LA, Valsecchi C, Pontiggia S, et al. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2014;12(3):329-336.
4. Kim HJ, Xu Y, Petri A, et al. Crystal structure of ADAMTS13 CUB domains reveals their role in global latency. Sci Adv. 2021;7(16):eabg4403.
5. Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237-e245.
6. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura | Hematology, ASH Education Program | American Society of Hematology. Accessed June 23, 2022. https://ashpublications.org/hematology/article/2015/1/631/20558/What-s-new-in-the-diagnosis-and-pathophysiology-of
7. Heath AB, Kremer Hovinga JA, Hubbard AR. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(6):1151-1153.
8. Lotta LA, Garagiola I, Palla R, et al. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
9. Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70(6):319-323.
10. Nguyen L, Li X, Duvall D, et al. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion. 2008;48(2):349-357.
11. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study | Annals of Hematology. Accessed August 3, 2024. https://link.springer.com/article/10.1007/s00277-009-0877-5
12. Bergstrand M, Hansson E, Delaey B, et al. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura. J Clin Pharmacol. 2022;62(3):409-421.
13. Owattanapanich W, Wongprasert C, Rotchanapanya W, et al. Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2019;25:1076029618825309.
14. Zwicker JI, Muia J, Dolatshahi L, et al. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood. 2019;134(13):1106-1109.
15. Knoebl P, Cataland S, Peyvandi F, et al. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2020;18(2):479-485.
16. Scully M, Rayment R, Clark A, et al. A British Society for Haematology Guideline: Diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. Br J Haematol. 2023;203(4):546-563.
17. Djulbegovic M, Tong J, Xu A, et al. Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Blood Adv. 2023;7(10):2132-2142.
18. Lee NCJ, Yates S, Rambally S, et al. Bortezomib in relapsed/refractory immune thrombotic thrombocytopenic purpura: A single-centre retrospective cohort and systematic literature review. Br J Haematol. 2024;204(2):638-643.
19. van den Berg J, Kremer Hovinga JA, Pfleger C, et al. Daratumumab for immune thrombotic thrombocytopenic purpura. Blood Adv. 2022;6(3):993-997.